Major Statin Meta-Analysis Finds Fewer Side Effects, But Transparency Questions Remain

A new, major meta-analysis in The Lancet is challenging long-standing concerns about statin side effects, suggesting that most are not causally linked to the drugs. Some researchers and clinicians, however, are questioning whether the analysis tells the full story.

Statins are among the most prescribed drugs in the U.S. Many cardiologists view them as life-saving treatments that reduce the risk of heart attack and stroke by lowering cholesterol. But while physicians and scientists mostly agree that statins are beneficial for those who have underlying risks of cardiovascular disease, their role as a preventative treatment in lower-risk individuals remains debated.

Statin product labels, including the FDA’s prescribing information in the U.S. and the summaries of product characteristics (SmPCs) in Europe and the U.K., list more than 60 side effects associated with the drug. The Cholesterol Treatment Trialists’ (CTT) Collaboration, a consortium focused on cholesterol and cardiovascular outcomes, has published influential meta-analyses since 2005. The one published in The Lancet in February 2026 is the group’s latest and largest, pooling data from 19 double-blind randomized trials comparing statins with placebo and including 123,940 participants with a median follow-up of 4.5 years. The authors concluded that only six commonly reported side effects are actually caused by the drug. 

Aside from muscle breakdown and new-onset diabetes, which had already been established in earlier analyses, only four additional side effects were statistically significant in the new analysis: elevated liver enzymes, abnormal liver function tests, changes in urine composition, and edema or swelling. 

Still, questions about data transparency and conflicts of interest have led some researchers to scrutinize the conclusions.

Some Clinicians See Findings as Reassuring for Statin Use

Supporters say the analysis offers a useful check on widely held beliefs about statin risks.

“This new meta-analysis from the CTT investigators is informative because it directly challenges concepts around perceived statin side effects and what has actually been shown in the gold standard, randomized, and important placebo-controlled clinical trial evidence,” says Gregg Fonarow, M.D., a cardiologist at UCLA Health who was not involved in the study.

Because much of the debate around statins centers on weighing the benefits and side effects, findings suggesting fewer side effects could give doctors and patients more confidence in using the drugs, continues Dr. Fonarow. He says that the lack of strong evidence linking many reported symptoms to statins supports their use for both primary and secondary prevention of cardiovascular events. “[Statins are] an effective, safe, and well-targeted way to lower your cardiovascular risk,” he stresses.

“Many people stop statins because of perceived side effects or fear of side effects, but this study shows that symptoms occurring during statin use would probably have occurred even if the patient was not taking statins,” adds Emily Herrett, Ph.D., an epidemiologist at the London School of Hygiene & Tropical Medicine who was not involved in the research, in a comment written for the All Ireland Science Media Centre in response to the study. 

“Many people stop statins because of perceived side effects or fear of side effects, but this study shows that symptoms occurring during statin use would probably have occurred even if the patient was not taking statins.”

Jeffrey Berger, M.D., a cardiologist at NYU Langone Health who was also not involved in the study, told New Scientist that the findings of the new meta-analysis are not “about telling people that they’re crazy, wrong, or don’t have [any] side effects, it’s about educating them to change their expectations.” 

Over the years, statin users have reported a range of side effects, including erectile dysfunction, blurry vision, sleep disturbances, dizziness, and throat pain. The CTT’s analysis found no clear evidence that statins were responsible for any of those symptoms.

Critics Raise Questions About Transparency, Funding, and Study Design

For Rita Redberg, M.D., a cardiologist at UCSF Health, there’s an elephant in the room: All of the trials included in the analysis were industry-funded (see Appendix), and the data is only available to those within the CTT, which she says raises questions about the validity of the conclusions.

Dr. Redberg says she first requested access to the data nearly 15 years ago, after CTT lead researcher, Rory Collins, FMedSci, presented earlier results at the 2012 European Society of Cardiology meeting. The presentation, which encouraged doctors to give statins to everyone over 50, sparked headlines and controversies across multiple media outlets.  

But her request, she said, went unfulfilled: “[The CTT] said they couldn’t share their data because they just hold it for industry, and industry doesn’t allow sharing of the data.”

Dr. Redberg is not alone. Other researchers say they requested access to the same dataset years ago and were also denied. Without access to the underlying data, independent investigations can be difficult.

The authors of the new analysis wrote that individual patient data from each trial were shared with the Cholesterol Treatment Trialists’ Collaboration for use in its meta-analyses and were not intended for broader release. “Requests for such data,” the authors explained, “should be made directly to the data custodians of each trial.” According to the CTT website, those custodians are either the original trial investigators or the sponsoring companies. 

The lack of data sharing in industry-funded trials is not new, says Lisa Parker, M.D., Ph.D., a bioethicist and practicing clinician at the University of Sydney who studies the influence of pharmaceutical funding on healthcare. 

“Individual participant data — that’s [the pharmaceutical companies’] resource. They’ve paid for that, so they’re going to keep it close to their chest, particularly if it shows something they don’t want people to see,” she says. 

“Individual participant data — that’s [the pharmaceutical companies’] resource. They’ve paid for that, so they’re going to keep it close to their chest, particularly if it shows something they don’t want people to see.”

Pharmaceutical companies have both the incentive and the resources to fund large clinical trials, which can shape what gets studied and what doesn’t, adds Dr. Parker. “[They’re] going to sponsor research that’s in their best interest,” she says, adding that statin manufacturers, for example, “[aren’t] going to look at the benefits of exercise on cholesterol. They’re not going to dedicate the same amount of resources to look at harms. Again, it just makes sense.”

Concerns About Conflicts of Interest

Beyond questions about transparency surrounding the data used in the CTT’s meta-analysis, Beatrice Golomb, M.D., Ph.D., a professor of medicine at the University of California, San Diego, says there are also potential conflicts of interest to consider. 

“There’s an enormous body of literature showing that industry conflict of interest is associated strongly with results — and especially conclusions — of studies,” she says. “Once people involve industry and take money [from them], subtle, often unconscious conflicts of interest come into play.”

“Once people involve industry and take money [from them], subtle, often unconscious conflicts of interest come into play.”

According to a 2007 study, trials funded by statin manufacturers were about 20 times more likely to report favorable results and 35 times more likely to reach favorable conclusions on the drugs being tested.

Dr. Golomb says her own research and clinical observations also shape her concerns. She and her colleagues conducted a clinical trial on statins, published in 2004, that linked statin use to cognitive problems, including temporary memory loss — an association the new analysis suggests is not caused by the drug. Despite the newer research, Dr. Golomb stands by her patients’ reports, noting that their cognitive symptoms emerged while they were taking statins and resolved when the medication was stopped. 

At a press conference announcing the study, MedShadow asked how the authors addressed potential conflicts of interest. Lead author Christina Reith, Ph.D., a researcher and physician consultant at the University of Oxford, said that while the individual trials included in the analysis were originally funded by the industry, the meta-analysis itself was not. 

In the study’s disclosures, several authors report current or past financial ties to pharmaceutical companies, including research funding, consulting work, and employment.

Could Methodology Have Influenced Findings?

Double-blind, placebo-controlled randomized clinical trials are well-suited to assessing benefits across large groups and helping justify use, says Dr. Golomb, “but even if harms only occur in small [groups], they’re still important to the people who experience them.”

People who are unlikely to benefit from a drug, such as certain older adults and those who have previously reported side effects from the same class of medication, are typically excluded from clinical trials during a run-in period, says Dr. Golomb. This phase occurs before randomization and may involve giving participants a placebo or the study drug to screen out those who can’t tolerate it.

Because many of the trials included in the new meta-analysis used run-in periods, some participants may have received a statin before randomization, and those who experienced side effects could have been excluded from continuing in the study. In the JUPITER trial, for example, participants who showed early hypersensitivity to statins were removed.

Run-in periods are common in large cardiovascular randomized trials and are often used to improve adherence and reduce early dropouts, says Ritu Goel, M.D., an integrative psychiatrist, author, and member of MedShadow’s Health and Medical Advisory panel, who has been involved in clinical trials examining medication side effects. As a result, certain adverse events, particularly subjective symptoms such as muscle pain or fatigue, may be underestimated in the randomized population. “This doesn’t invalidate the trials,” Dr. Goel adds, “but it does mean the findings are most applicable to people who can already tolerate statins, rather than to all patients starting therapy.”

Methodological choices beyond participant selection can also shape which side effects appear in a meta-analysis, notes Dr. Goel. In the CTT’s case, the authors set a threshold designed to minimize false positives among reported side effects with weaker causal links to statins. When thresholds are very strict, continues Dr. Goel, smaller or less common harms may not show up in the final results.

Other researchers agree that large datasets may miss rarer events. “While this study has a large sample to detect many side effects, it still may not be sufficient to provide conclusive evidence for rarer side effects,” Frank Moriarty, Ph.D., an associate professor at the Royal College of Surgeons in Ireland, wrote in a comment for the All Ireland Science Media Centre.

For those already taking statins, Dr. Golomb stresses the importance of consulting with their doctors if any side effects arise, regardless of whether they are listed in large studies. 

Dr. Redberg agrees. “As doctors, we’re not treating a group,” she says. “We’re treating the patient in front of us.”

Appendix

MedShadow has compiled a list of the 19 studies included in the statin vs placebo meta-analysis and their funders: 

1. Reith, C., Blackwell, L., Emberson, J. R., Preiss, D., Spata, E., Davies, K., Halls, H., Harper, C., Holland, L., Wilson, K., Humphrey, R., Roddick, A. J., Cannon, C. P., Davis, B. R., Durrington, P. N., Goto, S., Hitman, G. A., Hovingh, G. K., Koenig, W., . . . Zannad, F. (2026). Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials. The Lancet
2. Viatris. (2024). HIGHLIGHTS OF PRESCRIBING INFORMATION [Prescribing information].
3. Baigent, C., Keech, A., Kearney, P. M., Blackwell, L., Buck, G., Pollicino, C., Kirby, A., Sourjina, T., Peto, R., Collins, R., & Simes, R. (2005). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. The Lancet, 366(9493), 1267–1278
4. Reith, C., Baigent, C., Blackwell, L., Emberson, J., Spata, E., Davies, K., Halls, H., Holland, L., Wilson, K., Armitage, J., Harper, C., Preiss, D., Roddick, A., Keech, A., Simes, J., Collins, R., Barnes, E., Fulcher, J., Herrington, W. G., . . . Yamaguchi, J. (2022). Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. The Lancet, 400(10355), 832–845.
5. O’Donnell, K. (2026, February 6). Risks of side effects from statins may be overstated – Expert Reaction. Science Media Centre All Ireland.
6. Wong, C. (2026, February 11). Statins don't cause most of the side effects listed on their labels. New Scientist.
7. Chen, S., & Zhang, J. (2025). Association between statin use and erectile dysfunction: Results from the National Health and Nutrition Examination Survey. Medicine, 104(44), e44423.
8. Mizranita, V., & Pratisto, E. H. (2015). Statin-associated ocular disorders: the FDA and ADRAC data. International Journal of Clinical Pharmacy, 37(5), 844–850.
9. Trambowicz, K., Gorzelak-Pabis, P., Durma, A., Pypec, A., Lis, E., Rozmarynowska, I., Jurzak, N., Ignaczak, M., & Broncel, M. (2018). Statin use and sleep disturbance – Own experience. Atherosclerosis, 275, e229.
10. Malik, S., & Cohen, P. R. (2022). Rosuvastatin-Induced dizziness and pruritus: A case report and summary of Statin-Associated dizziness and pruritus. Cureus, 14(9), e29014.
11. Pop, M., Hayes, C., & Coggin, T. (2023). Atorvastatin hypersensitivity reaction within 24 hours of first dose. The American Journal of Emergency Medicine, 66, 175.e3-175.e4.
12. Bero, L., Oostvogel, F., Bacchetti, P., & Lee, K. (2007). Factors Associated with Findings of Published Trials of Drug–Drug Comparisons: Why Some Statins Appear More Efficacious than Others. PLoS Medicine, 4(6), e184.
13. Golomb, B. (2003, August 1). Statins and Non-Cardiac endpoints. Grantome.
14. Evans, M. A., & Golomb, B. A. (2009). Statin‐Associated Adverse Cognitive Effects: Survey Results from 171 Patients. Pharmacotherapy the Journal of Human Pharmacology and Drug Therapy, 29(7), 800–811.
15. Laursen, D. R. T., Paludan-Müller, A. S., & Hróbjartsson, A. (2019). Randomized clinical trials with run-in periods: frequency, characteristics and reporting
    Clinical Epidemiology, Volume 11, 169–184.
16. Ridker, P. M. (2003). Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of Low-Density lipoprotein cholesterol and elevated High-Sensitivity C-Reactive protein. Circulation, 108(19), 2292–2297.
17. Goel, R., Hong, J. S., Findling, R. L., & Ji, N. Y. (2018). An update on pharmacotherapy of autism spectrum disorder in children and adolescents. International Review of Psychiatry, 30(1), 78–95.